Abstract The prognosis of follicular lymphoma could vary with the tumor immune microenvironment. We evaluated the prognostic value of serum levels of ten cytokines. Our study cohort included 60 follicular lymphoma patients and 20 controls. Serum was available at diagnosis in 31 patients, at first relapse in 18, and complete remission in 11. Bioplex technology was used for determination of nine cytokines [interleukin (IL
Introduction
Follicular lymphoma (FL) is the second most frequent type of adult B-cell non-Hodgkin lymphoma (NHL) [1] . Considerable clinical heterogeneity and wide variation in survival among patients are found: In some patients, the disease is indolent and slowly progressive over a period of many years, whereas in others, it progresses rapidly, often to aggressive lymphoma, and patients die of their disease. The median survival is 8-10 years [2] , but recent reports suggest that prognosis has been improved [3, 4] . A number of clinical prognostic variables have been described. The Follicular Lymphoma International Prognostic Index (FLIPI) [5] , which measures five variables including age, Ann Arbor stage, hemoglobin level, number of nodal sites, and lactate dehydrogenase (LDH) level, identifies three prognostic groups with distinct survival probabilities. The FLIPI score is also helpful to compare different patient series, but its relevance for evaluating new treatments at diagnosis remains controversial [6] .
Recent studies have shown that the cellular microenvironment influences the prognosis of patients with FL [7] . Whole-genome microarray analysis of diagnostic biopsies has revealed that FL patients with poor and good outcomes are distinguishable by immune microenvironment-associated gene signatures [8] . The gene signature associated with favorable outcome is rich in expression of T-cell genes, whereas the signature associated with poor outcome is characteristic of macrophages. These results have been confirmed by immunohistochemical analyses of diagnostic FL biopsies [9, 10] , which have demonstrated a prognostic correlation with the number of forkhead box protein P3 (FOXP3) T-regulatory (Treg) cells present within the tumor. In contrast, high numbers of CD68 + macrophages are an independent prognostic factor of worse outcome [11] , but this prognostic value is lost in patients treated with rituximab and chemotherapy [12] .
Cytokines are produced by both the tumor cells and the surrounding immune cells and play a crucial role in the regulation of key pathways of immunity. They are implicated in the pathogenesis of many lymphomas. Increased concentrations of various cytokines and angiogenic factors have been reported as biomarkers for use in early diagnosis and prognosis in Hodgkin [13] and non-NHLs [14] [15] [16] . Most published studies have investigated heterogeneous series of NHL with relatively few patients within each subtype [14] [15] [16] [17] . Our literature search revealed few specific studies of cytokines in FLs [18] .
Here, we tested the hypothesis that serum levels of ten cytokines largely involved in lymphoid development, proinflammatory or anti-inflammatory pathways, angiogenesis, and Th1/Th2 balance are associated with FL outcome.
Materials and methods

Study population
This study was done using the extensive bank of blood samples prospectively collected at the Centre Leon Berard in the 1990s. Serum cytokine levels [interleukin (IL)-1Ra, IL-6, IL-7, IL-10, IL-13, tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), basic fibroblast growth factor, and transforming growth factor beta (TGF-β)] were measured in 60 consecutive FL patients for whom samples were available and consent had been obtained according to the legislation in place between 1991 and 2002. Samples taken at diagnosis (n=31), at first relapse (n=18), and in complete remission (CR) (n=11) were available. Samples from 20 healthy volunteers obtained from the National Blood Service (Etablissement Français du Sang, Lyon, France) after informed consent served as controls. Clinical staging was performed according to the Ann Arbor classification system [19] . Staging included evaluation of patient clinical status, chest radiography, computerized tomography (CT) of the chest and abdomen, and bone marrow biopsy.
Measurements of cytokine levels
We measured ten cytokines known to be involved in Th1/Th2 balance (IL-6, IL-10, and IL-13), angiogenesis [VEGF, PDGF, and basic fibroblast growth factor (b-FGF)], anti-inflammatory pathways (TGF-β and IL-1Ra), and lymphoma pathogenesis (TNF-α and IL-7). Peripheral blood samples were collected using sterile tubes. Sera were isolated by centrifugation at 2,000 rpm and stored at −80°C until assayed. The Bioplex technology (BioRad, Marne la Coquette, France) combines the principle of a sandwich immunoassay with fluorescent bead-based technology, allowing individual and multiplex analysis of up to 100 different analytes in a single microtiter well [20] . The Bioplex assay for nine cytokines (IL-1Ra, IL-6, IL-7, IL-10, IL-13, TNF-α, VEGF, PDGF, and b-FGF) was carried out in 96-well microplates according to the manufacturer's instructions. Samples were analyzed in duplicate. Analysis of experimental data was done using five-parametric curve fitting. Inter-assay variability for individual cytokines was in the range of 1.0-9.8% and intra-assay variability in the range of 3.6-12.6% (information provided by BioRad). TGF-β human sandwich enzyme-linked immunosorbent assay was performed on HCl/ NaOH-treated serum samples as recommended by the manufacturer (R&D Systems, Lille, France).
Statistical analysis
All assessable patients were entered into the analysis and evaluated using SAS 8.2 software (SAS institute, Cary). Quantitative variables were described by the median and number of missed values. Comparisons between different cytokine levels were performed using the Wilcoxon nonparametric test or t test. Correlations between cytokine levels and clinicopathological characteristics were estimated using the Pearson test.
Survival estimates were calculated using the KaplanMeier method [21] . Differences in survival were assessed by the log-rank test. The p values were given as an exploratory indication; a level of 0.05 was considered significant. In multivariate analysis, we used Cox proportional hazards modeling and the likelihood ratio test to evaluate survival differences between groups. Cytokines levels were introduced in the models as continuous parameters, and results were expressed as the relative risk ratio for one unit change. Candidate variables for the selection procedure were those statistically significant at 0.1 level in the univariate analysis. Although not statistically significant in the univariate analysis, clinical status was also included in the model. The adequacy of the Cox model was tested, and the proportional hazards assumption was found to be reasonable [22] .
Results
Clinical characteristics of the patients
Patient characteristics, diagnosis, and staging are reported in Table 1 . The study included 26 women and 34 men. Median age at diagnosis was 53.4 years (44-87). Ten patients had stage I disease, eight had stage II, ten had stage III, and 31 had stage IV. Different treatment modalities were used. Patients with localized disease received involved-field radiotherapy alone or were followed without lymphoma-specific treatment. One patient received singleagent rituximab. Patients with disseminated disease were treated with either cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like regimens or chlorombucil and/or prednisone. The median follow-up for surviving patients was 9 years (95% CI, 7.3-12.4). Overall survival (OS) rates at 5 and 10 years were 80.9% (95% CI, 70.8-91.1) and 57.5% (95% CI, 47.2-72.4), respectively ( Fig. 1 ).
Serum cytokines concentration in FL patients and healthy controls
The serum concentrations of cytokines were compared between the samples from patients at diagnosis (n=31), first relapse (n=18), or complete remission (n=11) and from the 20 healthy controls. Median levels of cytokines (IL1-Ra, IL-6, IL-7, IL-10, IL-13, TNF-α, VEGF, PDGF, b-FGF, and TGF-β) are summarized in Table 2 .
Overall, serum levels of IL-1Ra, IL-6, IL-7, IL-10, IL-13, TNF-α, VEGF, and PDGF were higher in FL patients than in controls. In contrast, TGF-β levels were significantly lower in FL patients compared to healthy controls (p=0.00326; Table 2 ). Only few patients had detectable serum concentrations of b-FGF (12 of 60).
IL-6 levels correlated positively with IL-7 (R=0.45, p< 0.001), IL-10 (R= 0.58, p< 0.001), IL-13 (R= 0.57, p<0.001), and IL-1Ra (R=0.91, p<0.001). Similarly, IL-10 correlated with IL-6 (R=0.58, p<0.001), IL-13 (R=0.82, p<0.001), and IL-1Ra (R=0.5, p<0.001). VEGF correlated with PDGF (R=0.31; p=0.0027). TGF-β correlated with IL-7 (R=0.4, p<0.001) and PDGF (R=0.43, p<0.001).
Correlations between cytokine levels and clinicopathologic characteristics of FL patients
We analyzed the correlations between the serum levels of each cytokine and the clinicopathologic characteristics of the 31 FL patients tested at diagnosis. IL-6 levels correlated only with LDH (p=0.003). High IL-10 levels correlated with advanced stage (p=0.05), bone marrow involvement (p=0.05), and high FLIPI score (trend, p=0.07). IL-13 levels correlated with β-2 microglobulin (p=0.05). A high platelet count was strongly associated with high VEGF (p=0.0057), PDGF (p=0.0147), and TGF-β (p=0.0112).
No correlation was observed between leukocyte count and cytokines levels.
Univariate and multivariate analyses of prognostic factors
We analyzed prognostic factors for OS and progression-free survival (PFS) in the entire cohort of FL patients. The issue most likely to confound the relationship between cytokine levels and survival was patient clinical status (diagnosis, relapse, or complete remission) at time of cytokine measurement. We attempted to account for this confounding factor by including clinical status in the univariate analysis and found differences in favor of CR patients. These differences were not significant for either OS (p=0.14) or PFS (p=0.29).
Factors associated with shorter PFS in the univariate analysis were intermediate or high FLIPI score (p=0.0034), high LDH levels (p=0.0083), advanced stage (p=0.0206), and high VEGF levels (p=0.0625; Table 3 ). Patients with advanced stage (III-IV; p=0.0324), intermediate or high FLIPI score (2-5; p=0.0786), high serum levels of IL-10 f (p=0.0267), and β-2 microglobulin (p=0.0707) had shorter OS. In contrast, high serum levels of TGF-β were associated with long survival (p=0.0149; Table 3 ).
In multivariate analysis, the prognostic value of VEGF level (HR=1.003; p=0.0393) for PFS was independent of LDH level (HR=2.675; p=0.005) and clinical status (Table 4 ; Fig. 2 ). Independent prognostic factors associated with improved OS were early stage (I-II) (HR = 4.967; p=0.00178) and high serum levels of TGF-β (HR=0.932; p=0.0328; Table 4 , Fig. 3 ): A 1 ng/ml increase in TGF-β levels was coupled with a 7% decrease of the risk of death. 
Discussion
Gene expression profiling and immunohistochemistry studies suggest that the tumor microenvironment influences the biological behavior and clinical outcome of FL [8] [9] [10] [11] . Cytokines are key regulators of immune functions. In the tumor microenvironment, they influence the survival and proliferation of both tumor and stromal cells. A recent study of single nucleotide polymorphisms (SNPs) in various cytokines has highlighted their importance in FL survival [23] .
The present work focused on the cytokines possibly implicated in this tumor-microenvironment cross-talk. Many of these cytokines have been measured in the sera of lymphoma patients [14] [15] [16] [17] , but most of the mentioned studies involved heterogeneous groups of NHL and rarely evaluated the prognostic value of cytokines in each different subtype [18] . We specifically screened patients with FL using a novel multiplex technology [20] .
The median follow-up for our FL patients was 9 years, which is consistent with the median OS in this disease. Survival rates in our study were in accordance with those reported in the literature [5] .
Overall, serum levels of IL-1Ra, IL-6, IL-7, IL-10, IL-13, TNF-α, VEGF, and PDGF were higher in FL patients than in healthy controls. We found a correlation between the different Th2 cytokines (IL-6, IL-10, and IL-13), and between two angiogenic cytokines (VEGF and PDGF). Few patients (n=12) had detectable b-FGF, and this cytokine did not influence outcome; neither did PDGF.
Univariate analysis of prognostic factors indicated that disease stage, FLIPI score, β-2 microglobulin, LDH and Normal range for LDH is 105-313 IU/l; normal level for serum β-2 microglobulin ≤3 mg/ml. p=0.05 for log-rank test HR hazard ratio, R reference variable, 95% CI confidence interval, M male, F female also IL-10, VEGF, and TGF-β serum levels influenced patient outcome. Confirmation of the prognostic value of disease stage and LDH levels by multivariate analysis supports the validity of our series. Besides, two additional prognostic factors for FL were identified: VEGF and TGF-β. We did not include treatment in our analysis because we consider that this variable was highly dependent on patient clinical characteristics: Patients with localized disease received radiotherapy or were followed up without treatment, whereas patients with disseminated disease received chemotherapy, and our multivariate model already included clinical status at time of cytokine measurement. IL-10 is a crucial mediator of inflammation, apoptosis, Th1/ Th2 balance, and functions as autocrine growth factor in lymphoid tumors [24, 25] . Our finding of an adverse prognostic impact of increased IL-10 serum levels is in accordance with previous reports in high and intermediate NHL [14, 26] . Correlation between tumor mass indicators (advanced stage, medullar involvement, and high FLIPI score) and IL-10 serum levels suggests that tumor B cells might be the source of this anti-inflammatory cytokine [14, 27] .
TGF-β is a pleiotropic cytokine that affects the proliferation, survival, and differentiation of normal and malignant cells, including lymphocytes [28, 29] . We were intrigued by the finding that TGF-β serum levels were lower in FL patients than in healthy controls. Indeed, high serum levels of TGF-β were predictive of improved survival in FL patients. These preliminary findings suggest an implication of TGF-β in the physiopathology of FL. Interestingly, several recent studies have explored the involvement of the NS not significant, HR hazard ratio, R reference item, 95% CI confidence interval VEGF is one of the most potent angiogenic stimulants with several biologic effects, including the maintenance and the survival of newly formed blood vessels [34] . Its expression can be evaluated with different methods. We found that high serum concentrations of VEGF were associated with poorer PFS. This observation has also been reported in heterogeneous NHL series including different subtypes [15, 16] . One study has evaluated VEGF expression by immunochemical staining specifically in FL and has shown that patients whose biopsies display a diffuse VEGF staining have poorer OS than those with focal staining [35] . The same study has shown that the high microvessel density found in interfollicular areas of FL is predictive of progressive disease, poorer OS, and transformation to DLBCL [35] . These observations and ours suggest a potential role of angiogenesis in the physiopathology of FL. Several antiangiogenesis agents, including bevacizumab [36] and sorafenib, are currently under investigation in lymphoma clinical trials [37] . Testing these agents specifically in FL patients would provide insight into the pathogenesis of this disease.
In conclusion, our results on serum cytokine levels in patients with FL identified two cytokines of probable importance in the outcome of this disease. However, our study has several limitations. It was based on a retrospective analysis of a limited and heterogeneous series of FL patients receiving different treatments before the era of monoclonal antibodies. Rituximab, which is currently a standard treatment of FL, alters the cytokine milieu. Since only one patient of our series received rituximab, our results should be interpreted with some caution, and prospective validation of our findings is necessary.
Another limitation of our study is that cytokine measurements were performed in patients with different clinical status (diagnosis, relapse, or complete remission). Clearly, clinical status had an impact on cytokine serum levels, with better PFS for patients in CR. However, the fact that serum VEGF levels remained independently predictive of prognosis in multivariate analysis of PFS confirmed the importance of this cytokine in the physiopathology of FL.
Our data suggest that VEGF may play a role in FL progression. In contrast, we found that high serum levels of TGF-β were associated with improved survival. To our knowledge, these results have not been previously reported in the literature. Elucidating TGF-β and VEGF pathways in FL would be helpful to identify novel targets for tumor immunotherapy. 
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TGFb1 <= 18 (ng/ml) TGFb1 > 18 (ng/ml) Log Rank p=0.03 Fig. 3 Overall survival of patients with follicular lymphoma according to serum TGF-β levels. Median cytokine levels were used as cut-off values
